Groprinosin: instructions for using the medicine, structure, Contraindications
Active material: Inosine pranobex
When ATH: J05AX05
CCF: Immunostimulatory drug
ICD-10 codes (testimony): A60, A81.1, B00, B01, B02
When CSF: 09.01.05.03
Manufacturer: GRODZISK Pharmaceutical Works Polfa Co.. Ltd. (Poland)
Pharmaceutical form, composition and packaging
Pills white, round, lenticular, at the risk of dividing on one side; with uniform, smooth surface without blemishes and damage.
| 1 tab. | |
| inosine pranobex | 500 mg |
Excipients: potato starch, polyvinylpyrrolidone, magnesium stearate.
25 PC. – blisters (2) – packs cardboard.
Groprinosin: pharmachologic effect
Immunostimulatory drug with antiviral action. It is a complex, containing inosine and N,N-dimethylamino-2-propanol in molyarnom sootnoshenii 1:3.
The effectiveness of the complex is determined by the presence of inosine, the second component increases its availability to lymphocytes. Groprinosin stimulates biochemical processes in macrophages, It increases production of interleukin. Strengthens the synthesis of antibodies, enhances the proliferation of T-lymphocytes, T-helper cells, natural killer cells.
It stimulates the chemotactic and phagocytic activity of monocytes, macrophages and polymorphonuclear cells. Groprinosin inhibits the replication of DNA and RNA viruses by binding with ribosome cells and changes its stereochemical structure.
The drug was well tolerated, tk. It has low toxicity. It can be given to patients in the elderly with angina or chronic heart failure.
With timely use of the drug reduced the incidence of viral infections, reduced the duration and severity of the disease.
Use of the drug is indicated in patients with poor immune defenses.
When assigning Groprinosina as a subsidiary drug for infectious lesions of the skin and mucous membranes, caused by the herpes simplex virus, more rapid healing of the damaged surface, than the conventional method in the treatment of. Rarely there are new bubbles, edema, erosion and recurrence of the disease.
Groprinosin: pharmacokinetics
Absorption
After oral administration, the drug is well absorbed from the gastrointestinal tract and is characterized by good bioavailability.
Metabolism and excretion
Rapidly metabolized. Inosine is metabolized by cycle, typical of purine nucleotides, to form uric acid, level in blood serum which can sometimes increase. As a result, the formation of uric acid crystals in the urinary tract. There were no drug accumulation in the body.
Report the news. Complete elimination of the drug and its metabolites are excreted occurs during 48 no.
Groprinosin: testimony
- Immunodeficiency, caused by viral infections in patients with normal and impaired immune systems, incl. disease, caused by Herpes simplex virus types 1 and 2 (including genital herpes and cold sores at other sites);
- Subacute sclerosing panencephalitis.
Groprinosin: dosing regimen
The drug is taken orally after meal, at regular intervals (8 or 6 no) 3-4 times / day.
Adults administered at a dose of 3-4 g (from 6 to 8 tab.)/d, razdelennoy of 3-4 admission.
Children aged 2 to 12 years administered at a dose of 50 mg / kg / day, razdelennoy of 3-4 admission.
In adults and children at serious infectious diseases the dose may be increased individually under medical supervision to 100 mg / kg / day 4-6 receptions.
The drug is usually applied for 5 days, sometimes longer, depending on the disease. After an 8-day break course of treatment can be repeated.
The tablets are, with a little water.
Groprinosin: side effects
Development of possible adverse reactions in early treatment.
From the digestive system: decreased appetite, nausea, vomiting, diarrhea.
Other: a slight increase in the concentration of uric acid in blood and urine, allergic reactions.
Groprinosin: Contraindications
- Gout;
- Urolithiasis disease;
- Arrhythmia;
- Children up to age 2 years;
- Pregnancy;
- Lactation (breast-feeding);
- Hypersensitivity to the drug.
Groprinosin: Pregnancy and lactation
The drug is contraindicated in pregnancy and lactation (breast-feeding), tk. its safety in these patients has not been established.
Groprinosin: Special instructions
It should not be prescribed to patients with hyperuricemia in connection with the possibility of increasing the levels of uric acid in the serum and urine. If necessary, use of the drug in these patients should regularly monitor the content of uric acid in the body. Patients with a significant increase of uric acid is recommended to take the medication at the same time, lowering the level.
Patients with acute liver failure requires a reduction in dosage, tk. inosine pranobex metabolism occurs in the liver.
In elderly patients, dose adjustment is required.
Effects on ability to drive vehicles and management mechanisms
Patient, taking Groprinosin, no specific contraindications to the driving and maintenance of moving parts.
Groprinosin: overdose
Data on drug overdose Groprinosin not provided.
Drug Interactions
Immunosuppressants reduce the effectiveness of the drug.
Groprinosin: terms of dispensing from pharmacies
The drug is released under the prescription.
Groprinosin: terms and conditions of storage
The drug should be stored out of reach of children, dry, dark place at room temperature not exceeding 25 ° C. Shelf life – 3 year.
